Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$239.05 USD

239.05
718,021

+4.67 (1.99%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $239.04 -0.01 (0.00%) 5:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.

Cerner's (CERN) Acquisition by Oracle to Boost Patient Outcome

by Zacks Equity Research

Cerner's (CERN) buyout is likely to aid in growing its community presence as well as improve patient outcomes.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.

Integra (IART) Businesses Rebound Despite Supply Issues

by Zacks Equity Research

Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.

Medtronic (MDT) Businesses Rebound Amid Raging Pandemic

by Zacks Equity Research

Medtronic (MDT) is registering strong organic growth in the Cardiovascular, Neuroscience and Diabetes segments on product launches.

Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod

by Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.

Here's Why You Should Retain DexCom (DXCM) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Here's Why You Should Retain Haemonetics (HAE) Stocks for Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.

Medtronic's (MDT) INVOS System Gets FDA 510 (k) Clearance

by Zacks Equity Research

Medtronic's (MDT) INVOS 7100 system can deliver key signals to pediatric clinicians for making time-sensitive decisions

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Catalent (CTLT) owing to its robust facility expansion activities and a slew of strategic deals.

Here's Why You Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to strong segmental growth and bullish 2022 outlook.

FDA Approves Intuitive Surgical's (ISRG) Latest SureForm Stapler

by Zacks Equity Research

Intuitive Surgical's (ISRG) newest stapler is expected to result in better surgical outcomes.

Walgreens (WBA), Village MD Plan to Expand Into San Antonio

by Zacks Equity Research

Walgreens (WBA) and VillageMD to improve access to overall care for patients with chronic conditions by opening nine new Village Medical at Walgreens primary care practices in San Antonio.

Is John Hancock Multifactor Mid Cap ETF (JHMM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JHMM

Veeva's (VEEV) Data Cloud to Aid PharmaEssentia's New Product

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Commercial Cloud business.

LabCorp (LH) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

LabCorp (LH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

by Zacks Equity Research

Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.

Here's Why You Should Retain Charles River (CRL) Stock for Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.

Best Growth Stocks to Buy for December 15th

by Zacks Equity Research

CC, LH, and HCCI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 15, 2021

Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Veeva Systems (VEEV) owing to its strong product portfolio.

Study Favors Masimo's (MASI) SedLine for Better Patient Outcome

by Zacks Equity Research

Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.

Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses

by Zacks Equity Research

Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.

Henry Schein's (HSIC) New Deal Broadens Medical Supplies Arm

by Zacks Equity Research

The OMNIA Partners cooperative contract is expected to expand Henry Schein's (HSIC) offerings in the field of Point-of-Care testing, personal protective equipment and essential medical supplies.

CVS Health (CVS) Outlines Growth Strategy, Initiates 2022 View

by Zacks Equity Research

CVS Health's (CVS) new strategy capitalizes on the considerable opportunity to make health care more convenient, personalized and affordable for consumers.

Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JHMM